PARSIPPANY, N.J., Aug. 16 /PRNewswire/ -- Ferring Pharmaceuticals Inc., the makers of FIRMAGON® (degarelix for injection), is in the race to end prostate cancer as an official sponsor of the Great Prostate Cancer Challenge / Dash for Dad, the premier prostate cancer race series in the United States, led by ZERO – The Project to End Prostate Cancer. FIRMAGON® is a hormone antagonist therapy for advanced prostate cancer.
"ZERO's Dash for Dad exemplifies the determination needed to beat prostate cancer," said William Garbarini, Vice President, US Marketing, Ferring Pharmaceuticals Inc. "It is inspiring to see athletes, doctors and friends—but especially survivors and family members—race with such commitment to stop prostate cancer in its tracks. We are proud to support their efforts."
This year, ZERO expects more than 7,000 participants across 14 cities in the Great Prostate Cancer Challenge / Dash for Dad. Baltimore, Nashville, and Indianapolis are just a few of the cities where running races and walks will be held. The widespread exposure generated by the events will go a long way toward advancing the organization's mission—zero tolerance for prostate cancer.
The first Dash for Dad race took place in 2008 in an effort to promote prostate cancer awareness, early detection and research. To date, the national series has raised more than one million dollars. ZERO – The Project to End Prostate Cancer, dedicates the proceeds from each event to free prostate cancer screenings in the host community.
"We are thrilled Ferring has joined our race to end prostate cancer," said ZERO's CEO Skip Lockwood. "Their product FIRMAGON is an important treatment option for advanced prostate cancer patients, and reflects their determination to help provide effective treatment for patients suffering with this disease. Teaming up
|SOURCE Ferring Pharmaceuticals Inc.|
Copyright©2010 PR Newswire.
All rights reserved